---
title: "Sionna Therapeutics jumps nearly 40% in cracking Nasdaq debut"
date: "2025-02-08 02:15:26"
summary: "** Shares of drug developer Sionna Therapeutics (SION.O) jump as much as 38.9% in their Nasdaq debut; last up 38.1% at $24.86** Stock opened for trading at $25 vs $18 IPO price, giving it a market capitalization of $1.06 billion** SION sold ~10.6 million shares, 20% more than initially offered,..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Shares of drug developer Sionna Therapeutics (SION.O) jump as much as 38.9% in their Nasdaq debut; last up 38.1% at $24.86

\*\* Stock opened for trading at $25 vs $18 IPO price, giving it a market capitalization of $1.06 billion

\*\* SION sold ~10.6 million shares, 20% more than initially offered, at the top end of its marketed range of $16 to $18 apiece to raise $190.6 million

\*\* Founded in 2019 and previously known as Sling Therapeutics, SION is developing drugs to treat cystic fibrosis

\*\* SION is vying for a slice of the cystic fibrosis market that is dominated by drugmaker Vertex Pharmaceuticals

\*\* Vertex booked almost $10 billion in sales in 2023 and has significantly impacted cystic fibrosis treatment

\*\* SION is evaluating its experimental drug candidates SION-719 and SION-451 in early-stage trials in Australia

\*\* Prior to the IPO, SION had raised about $330 million from investors, including RA Capital and TPG's Rise Fund

\*\* Goldman Sachs, TD Cowen, Stifel and Guggenheim Securities were the underwriters

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3OY1LC:0-sionna-therapeutics-jumps-nearly-40-in-cracking-nasdaq-debut/)
